Search
National R&D

ACTINODEEPSEA

Bioprospecting actinobacteria from Portuguese deep-sea waters for the production of novel secondary metabolites with pharmaceutical and biotechnological applications

Principal Investigator
Group Leader

Maria de Fátima Carvalho holds a degree in Microbiology and a PhD in Biotechnology from the Portuguese Catholic University. She is currently principal investigator at CIIMAR, where she leads the research team Microbial Biodegradation and Bioprospecting. Her research interests are focused on two main lines (i) development of biotechnological strategies for the removal of organic environmental pollutants, with special emphasis on fluorinated compounds and (ii) bioprospecting actinobacteria from diverse sources (from terrestrial to marine environments) for the discovery of novel molecules with relevant biotechnological applications.

RESEARCH GROUPS:

No results found.

Actinobacteria are a large group of Gram-positive bacteria, highly prolific in the production of bioactive secondary metabolites with a wide range of biological and pharmaceutical properties. Most of known actinobacterial species are of terrestrial origin, but it has been recently shown that they are also "true" habitants of the oceans and are a proven source of novel relevant secondary metabolites. The present proposal intends to explore the untapped and vast deepsea area of Portugal in terms of native actinobacteria and their potential to produce novel secondary metabolites with antimicrobial, anti-inflammatory, anticancer and antiobesity activities and biosurfactants. To accomplish the objectives of the project, both culture-dependent and independent approaches will be employed. Actinobacteria will be isolated from various deep-sea samples from continental Portugal and Azores and Madeira islands and screened for their capacity to produce target bioactive secondary metabolites. Metagenomic libraries will be constructed from selected deep-sea samples and will be screened for genes encoding biologically active compounds. The most promising bioactive metabolites will be subjected to detailed chemical analyses for identification of the chemical structure(s) responsible for the bioactivity. Some actinobacterial isolates will be also selected for genome sequencing. It is the aim of the project to discover novel drugs that may help in the future to fight diseases such as cancer, multiresistant bacterial infections and obesity that affect millions of people worldwide, and novel biosurfactants that can meet the needs of bioeconomy-based societies.

Funding
Other projects